Discontinued — last reported Q1 '26
Alliance Revenue - Reblozyl — Sales
Merck & Co. Alliance Revenue - Reblozyl — Sales decreased by 54.6% to $148.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 37.8%, from $238.00M to $148.00M. Over 2 years (FY 2023 to FY 2025), Alliance Revenue - Reblozyl — Sales shows an upward trend with a 57.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests growing market demand and successful commercial execution for the product, while a decrease may signal competitive pressure or market saturation.
Detailed definition
This metric captures the total revenue recognized from a collaborative arrangement involving the commercialization of a...
Peer comparison
Comparable to royalty revenue or profit-sharing income reported by other pharmaceutical companies under co-promotion or co-development agreements.
mrk_segment_alliance_revenue_reblozyl_salesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $104.00M | $66.00M | $78.00M | $85.00M | $94.00M | $53.00M | $191.00M | $141.00M | $180.00M | $200.00M | $221.00M | $238.00M | $214.00M | $272.00M | $326.00M | $148.00M |
| QoQ Change | — | — | — | -36.5% | +18.2% | +9.0% | +10.6% | -43.6% | +260.4% | -26.2% | +27.7% | +11.1% | +10.5% | +7.7% | -10.1% | +27.1% | +19.9% | -54.6% |
| YoY Change | — | — | — | — | — | -18.3% | +42.4% | -32.1% | — | +65.9% | +91.5% | +277.4% | +15.7% | +68.8% | +18.9% | +36.0% | +47.5% | -37.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s alliance revenue - reblozyl — sales?
- Merck & Co. (MRK) reported alliance revenue - reblozyl — sales of $148.00M in Q1 2026.
- How has Merck & Co.'s alliance revenue - reblozyl — sales changed year-over-year?
- Merck & Co.'s alliance revenue - reblozyl — sales decreased by 37.8% year-over-year, from $238.00M to $148.00M.
- What is the long-term trend for Merck & Co.'s alliance revenue - reblozyl — sales?
- Over 2 years (2023 to 2025), Merck & Co.'s alliance revenue - reblozyl — sales has grown at a 57.6% compound annual growth rate (CAGR), from $423.00M to $1.05B.
- What does alliance revenue - reblozyl — sales mean?
- The company's share of total revenue generated from the sales of a co-developed pharmaceutical product.